Clinical Trial Detail

NCT ID NCT02632721
Title A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

acute myeloid leukemia

Therapies

BI 836858 + Decitabine

Decitabine

Age Groups: senior adult

No variant requirements are available.